ADVB — ADVANCED BIOMED Cashflow Statement
0.000.00%
Last trade - 00:00- $39.17m
- $36.51m
Annual cashflow statement for ADVANCED BIOMED, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -1.84 | -4.03 | -3.73 | -2.78 |
| Depreciation | ||||
| Non-Cash Items | -0 | 1.66 | 0.129 | -0.053 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 1.31 | 1.5 | 0.275 | 0.31 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -0.474 | -0.741 | -2.96 | -2.13 |
| Capital Expenditures | -0.025 | -1.31 | -0.213 | -0.074 |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | 0 | 0.228 | -0.05 | 0 |
| Acquisition of Business | ||||
| Sale of Business | ||||
| Sale of Fixed Assets | ||||
| Cash from Investing Activities | -0.025 | -1.08 | -0.263 | -0.074 |
| Financing Cash Flow Items | — | — | -0.553 | 0.209 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0.697 | 6.1 | 0.458 | 1.87 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0 | 4.72 | -2.16 | -0.014 |